Blair Curtis  Jackson net worth and biography

Blair Jackson Biography and Net Worth

COO of Alkermes
Blair Jackson serves as Alkermes’ Executive Vice President and Chief Operating Officer. In this role, Mr. Jackson is responsible for Alkermes’ strategic planning and corporate services, leading the organization’s global Operations, Quality, Finance, Information Technology, and Corporate Planning functions. 

Mr. Jackson has more than 20 years of diverse scientific and business development experience within the pharmaceutical industry. Since joining Alkermes in 1999, Mr. Jackson has served in a variety of roles in both a scientific and corporate capacity, including his most recent roles as Senior Vice President of Corporate Planning. He currently serves on the Board of Directors of Synchronicity Pharma. 

Mr. Jackson earned a bachelor’s degree in Biochemistry from the University of Calgary in Alberta, Canada, a bachelor’s degree in Chemical Engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in Chemical Engineering from the Massachusetts Institute of Technology.

What is Blair Curtis Jackson's net worth?

The estimated net worth of Blair Curtis Jackson is at least $2.38 million as of April 20th, 2022. Mr. Jackson owns 87,915 shares of Alkermes stock worth more than $2,378,980 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Jackson may own. Additionally, Mr. Jackson receives an annual salary of $1,050,000.00 as COO at Alkermes. Learn More about Blair Curtis Jackson's net worth.

How old is Blair Curtis Jackson?

Mr. Jackson is currently 51 years old. There are 7 older executives and no younger executives at Alkermes. The oldest executive at Alkermes is Dr. Floyd E. Bloom M.D., Founder, who is 87 years old. Learn More on Blair Curtis Jackson's age.

What is Blair Curtis Jackson's salary?

As the COO of Alkermes plc, Mr. Jackson earns $1,050,000.00 per year. There are 3 executives that earn more than Mr. Jackson. The highest earning executive at Alkermes is Mr. Richard F. Pops, Chairman & CEO, who commands a salary of $2,300,000.00 per year. Learn More on Blair Curtis Jackson's salary.

How do I contact Blair Curtis Jackson?

The corporate mailing address for Mr. Jackson and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Blair Curtis Jackson's contact information.

Has Blair Curtis Jackson been buying or selling shares of Alkermes?

Blair Curtis Jackson has not been actively trading shares of Alkermes during the last quarter. Most recently, Blair Curtis Jackson sold 49,999 shares of the business's stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $29.61, for a transaction totalling $1,480,470.39. Following the completion of the sale, the chief operating officer now directly owns 87,915 shares of the company's stock, valued at $2,603,163.15. Learn More on Blair Curtis Jackson's trading history.

Who are Alkermes' active insiders?

Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.

Are insiders buying or selling shares of Alkermes?

During the last year, insiders at the sold shares 4 times. They sold a total of 81,601 shares worth more than $2,454,554.32. The most recent insider tranaction occured on March, 18th when SVP Christian Todd Nichols sold 10,417 shares worth more than $292,717.70. Insiders at Alkermes own 4.8% of the company. Learn More about insider trades at Alkermes.

Information on this page was last updated on 3/18/2024.

Blair Curtis Jackson Insider Trading History at Alkermes

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2022Sell49,999$29.61$1,480,470.3987,915View SEC Filing Icon  
See Full Table

Blair Curtis Jackson Buying and Selling Activity at Alkermes

This chart shows Blair Curtis Jackson's buying and selling at Alkermes by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alkermes Company Overview

Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $27.06
Low: $26.91
High: $27.33

50 Day Range

MA: $28.50
Low: $26.40
High: $32.56

2 Week Range

Now: $27.06
Low: $22.01
High: $33.71

Volume

93,443 shs

Average Volume

1,878,260 shs

Market Capitalization

$4.52 billion

P/E Ratio

13.07

Dividend Yield

N/A

Beta

0.57